Drug Database
Back to search

Netherlands· NL-14f076d69454

Ritmoforine Retard 250 mg, tabletten met gereguleerde afgifte

A disopyramide product containing disopyramidediwaterstoffosfaat, registered in Netherlands by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 9 of our 19 countries.

ATC C01BA03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRitmoforine Retard 250 mg, tabletten …ATCC01BA03REGISTER NO.NL-14f076d69454PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about disopyramidediwaterstoffosfaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Disopyramide is registered in 9 of 19 countries.

Countries holding a registration under ATC C01BA03 (disopyramide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search disopyramide products by name

Disopyramide · ATC C01BA03

9 / 19 countries

  • Belgiumprice
  • Canada
  • Finlandprice
  • Franceprice
  • Japan
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DISOPYRAMIDEDIWATERSTOFFOSFAAT
Manufacturer
CHEPLAPHARM Arzneimittel GmbH
Country
Netherlands (NL)
ATC code
C01BA03
ATC class
Disopyramide
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    08613

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

341 interactions on record for disopyramide.

Graded by severity as the source publishes them — 138 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check disopyramide against other medicinesHow interaction checks work

Disopyramide · interactions on record

341 records

  • 138 severe
  • 182 moderate
  • 10 minor
  • 11 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Disopyramide in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All disopyramide products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Belgium · Rythmodan, Rythmodan Long Action
  • Spain · Dicorynan
  • France · Isorythm L.P., Rythmodan
  • United Kingdom (Northern Ireland) · Disopyramide Neon, Disopyramide Neon Healthcare
  • Italy · Ritmodan, Ritmodan Retard
  • Luxembourg · Rythmodan, Rythmodan Long Action

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/858e34a9-3239-48e9-bebf-ed7d3287e5ff
GET /v1/drugs/858e34a9-3239-48e9-bebf-ed7d3287e5ff?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet met gereguleerde afgifte",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h08613_smpc.pdf",
  "strength": null,
  "atc_label": "Disopyramide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg08613",
  "excipients": [
    "GLUCOSE 0-WATER",
    "GLYCEROLMONOSTEARAAT (E 471)",
    "HYPROMELLOSE (E 464)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POVIDON (E 1201)",
    "PROPYLEENGLYCOL (E 1520)",
    "SACCHAROSE"
  ],
  "substances": [
    "DISOPYRAMIDEDIWATERSTOFFOSFAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h08613.pdf",
  "authorised_at": "1980/09/10",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "08613",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about disopyramide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console